Impact of red blood cell transfusion dose density on progression-free survival in lower-risk myelodysplastic syndromes patients by Smith, Alexandra Gwen & Yu, Ge
This is a repository copy of Impact of red blood cell transfusion dose density on 
progression-free survival in lower-risk myelodysplastic syndromes patients.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/149546/
Version: Published Version
Article:
de Swart, Louise, Crouch, Simon orcid.org/0000-0002-3026-2859, Hoeks, Marlijn et al. (27
more authors) (2019) Impact of red blood cell transfusion dose density on progression-free
survival in lower-risk myelodysplastic syndromes patients. Haematologica-The hematology
journal. ISSN 0390-6078 
https://doi.org/10.3324/haematol.2018.212217
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
Impact of red blood cell transfusion dose density on 
progression-free survival in lower-risk myelodysplastic
syndromes patients
by Louise de Swart, Simon Crouch, Marlijn Hoeks, Alex Smith, Saskia Langemeijer, Pierre Fe-
naux, Argiris Symeonidis, Jaroslav Čermák, Eva Hellström-Lindberg, Reinhard Stauder, Guil-
lermo Sanz, Moshe Mittelman, Mette Skov Holm, Luca Malcovati, Krzysztof Mądry, Ulrich
Germing, Aurelia Tatic, Aleksandar Savic, Antonio Medina Almeida, Njetočka Gredelj-Šimec,
Agnes Guerci-Bresler, Odile Beyne-Rauzy, Dominic Culligan, Ioannis Kotsianidis, Raphael It-
zykson, Corine van Marrewijk, Nicole Blijlevens, David Bowen, and Theo de Witte
Collaborative Groups: EUMDS Registry Participants) 
Haematologica 2019 [Epub ahead of print]
Citation: Louise de Swart, Simon Crouch, Marlijn Hoeks, Alex Smith, Saskia Langemeijer, 
Pierre Fenaux, Argiris Symeonidis, Jaroslav ermák, Eva Hellström-Lindberg, Reinhard Stauder, 
Guillermo Sanz, Moshe Mittelman, Mette Skov Holm, Luca Malcovati, Krzysztof M dry, 
Ulrich Germing, Aurelia Tatic, Aleksandar Savic, Antonio Medina Almeida, Njeto ka Gredelj-Šimec,
Agnes Guerci-Bresler, Odile Beyne-Rauzy, Dominic Culligan, Ioannis Kotsianidis, Raphael Itzykson,
Corine van Marrewijk, Nicole Blijlevens, David Bowen, and Theo de Witte. Collaborative Groups:
EUMDS Registry Participants). Impact of red blood cell transfusion dose density on progression-free 
survival in lower-risk myelodysplastic syndromes patients
Haematologica. 2019; 104:xxx
doi:10.3324/haematol.2018.212217
Publisher's Disclaimer.
E-publishing ahead of print is increasingly important for the rapid dissemination of science.
Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that
have completed a regular peer review and have been accepted for publication. E-publishing
of this PDF file has been approved by the authors. After having E-published Ahead of Print,
manuscripts will then undergo technical and English editing, typesetting, proof correction and
be presented for the authors' final approval; the final version of the manuscript will then
appear in print on a regular issue of the journal. All legal disclaimers that apply to the
journal also pertain to this production process.
 Copyright 2019 Ferrata Storti Foundation.
Published Ahead of Print on June 6, 2019, as doi:10.3324/haematol.2018.212217.
1 
Impact of red blood cell transfusion dose density on progression-free survival 
in lower-risk myelodysplastic syndromes patients 
 
Louise de Swart
1
, Simon Crouch
2
, Marlijn Hoeks
1,3
, Alex Smith
2
, Saskia Langemeijer
1
, Pierre Fenaux
4
, 
Argiris Symeonidis
5
, Jaroslav Čermák
6
, Eva Hellström-Lindberg
7
, Reinhard Stauder
8
, Guillermo Sanz
9
, 
Moshe Mittelman
10
, Mette Skov Holm
11
, Luca Malcovati
12
, Krzysztof Mądry
13
, Ulrich Germing
14
, 
Aurelia Tatic
15
, Aleksandar Savic
16
, Antonio Medina Almeida
17
, Njetočka Gredelj-Šimec
18
, Agnes 
Guerci-Bresler
19
, Odile Beyne-Rauzy
20
, Dominic Culligan
21
, Ioannis Kotsianidis
22
, Raphael Itzykson
4
, 
Corine van Marrewijk
1
, Nicole Blijlevens
1
, David Bowen
23
 and Theo de Witte
24
, on behalf of the 
EUMDS Registry Participants 
 
1
Department of Hematology, Radboud university medical center, Nijmegen, The Netherlands;  
2
Epidemiology 
and Cancer Statistics Group, Department of Health Sciences, University of York, York, United Kingdom;  
3
Centre for Clinical Transfusion Research, Sanquin Research, Leiden, The Netherlands;  
4
Service 
d'Hématologie, Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris and Université Paris 7, Paris, 
France;  
5
Department of Medicine, Division of Hematology, University of Patras Medical School, Patras, 
Greece;  
6
Department of Clinical Hematology, Inst. of Hematology & Blood Transfusion, Praha, Czech 
Republic;  
7
Department of Medicine, Division of Hematology, Karolinska Institutet, Stockholm, Sweden;  
8
Department of Internal Medicine V (Haematology and Oncology), Innsbruck Medical University, Innsbruck, 
Austria;  
9
Department of Haematology, Hospital Universitario y Politécnico La Fe, Valencia, Spain;  
10
Department of Medicine A, Tel Aviv Sourasky (Ichilov) Medical Center and Sackler Medical Faculty, Tel Aviv 
University, Tel Aviv, Israel;  
11
Department of Haematology, Aarhus University Hospital, Aarhus, Denmark;  
12
Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, 
Italy;  
13
Department of Haematology, Oncology and Internal Medicine, Warszawa Medical University, 
Warszawa, Poland;  
14
Department of Hematology, Oncology and Clinical Immunology, Universitätsklinik 
Düsseldorf, Düsseldorf, Germany;  
15
Center of Hematology and Bone Marrow Transplantation, Fundeni 
Clinical Institute, Bucharest, Romania;  
16
Clinic of Hematology - Clinical Center of Vojvodina, Faculty of 
Medicine, University of Novi Sad, Novi Sad, Serbia; 
17
Department of Clinical Hematology, Hospital da Luz, 
Lisbon, Portugal;  
18
Department of Internal Medicine, Division of Hematology, Merkur University Hospital, 
Zagreb, Croatia;  
19
Service d'Hématologie, Centre Hospitalier Universitaire Brabois Vandoeuvre, Nancy, 
France;  
20
Service de Médecine Interne, IUCT-Oncopole, CHU Toulouse, France;  
21
Department of 
Haematology, Aberdeen Royal Infirmary, Aberdeen, United Kingdom;  
22
Department of Hematology, 
Democritus University of Thrace Medical School, University Hospital of Alexandroupolis, Alexandroupolis, 
Greece;  
23
St. James's Institute of Oncology, Leeds Teaching Hospitals, Leeds, United Kingdom;  
24
Department 
of Tumor Immunology - Nijmegen Center for Molecular Life Sciences, Radboud university medical center, 
Nijmegen, The Netherlands 
 
Correspondence: Theo de Witte, Department of Tumorimmunology, Nijmegen Institute of Life 
Sciences, Radboud university medical center, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands. 
E-mail: theo.dewittte@radboudumc.nl 
 
Running head: Transfusion dose density in lower-risk MDS (37 characters) 
 
Word count: Abstract: 245, Text: 3735 
Table: 1, Figures: 3, Supplementary Tables: 2, Supplementary Figures: 4 
References: 37 
 
2 
Acknowledgements: The authors and members of the steering committee of the EUMDS registry 
would like to thank all local investigators and operational team members for their contribution. 
 
Funding: 
The work of the EUMDS Registry is supported by an educational grant from Novartis Pharmacy B.V. 
Oncology Europe, and Amgen Limited. This work is part of the MDS-RIGHT activities, which has 
received funding from the European Union’s Horizon 2020 research and innovation programme 
under grant agreement No 634789 - “Providing the right care to the right patient with 
MyeloDysplastic Syndrome at the right time”. 
 
Authorship 
-Contributions: Design: LdS, SC, MH, AS, SL, DB, and TDW; provision of patients, assembly of data: SC, 
AS, SL, PF, ASY, JC, EHL, RS, GS, MM, MSH, LM, KM, UG, AT, ASA, AMA, NGS, AGB, OBR, DC, IK, RI, 
CvM, DB, and TdW; statistical analysis: LdS, SC, AS, DB, and TdW; manuscript writing: all authors; ﬁnal 
approval: all authors. 
-Disclosure of conflicts-of-interests:  
PF: Research funding and honoraria from Amgen, Astex, Celgene, Janssen, Novartis, and Roche; ASY: 
honoraria and consulting fees from Amgen, Celgene/GenesisPharma, Genzyme/Sanofi, Gilead, 
Janssen-Cilag, Pfizer, MSD, and Novartis; EHL: research funding from Celgene; GS: research funding 
and honoraria from Amgen, Celgene, and Novartis, and consulting fees from Amgen, Boehringer-
Ingelheim, Celgene, MSD, and Novartis; MSH: research funding from Celgene; UG: research funding 
and honorarium from Novartis; ASA has received honoraria and consulting fees from Hoffmann-La 
Roche, MSD, and Pfizer; AMA: honoraria from Alexion and BMS, and consulting fees from Celgene, 
Novartis, and Servier; RI: research funding and honoraria from Amgen, BMS, Celgene, Janssen, 
Oncoethix (now Merck MSD) and Sanofi, and consulting fees from Karyopharm, Novartis, and Otsuka; 
CvM: funded by the EUMDS project budget; NB: research funding from Ariad, Astellas, BMS, Celgene, 
MSD, Novartis, Pfizer, and Xenikos, and educational grants from Celgene, Janssen Cilag, and Novartis; 
TdW: research funding and honorarium from Amgen, Celgene, and Novartis, as project coordinator 
EUMDS. The remaining authors (LdS, SC, MH, AS, SL, JC, RS, MM, LM, KM, AT, NGS, AGB, OBR, DC, IK, 
and DB) declare no competing financial interests. 
 
Key points 
• The new outcome parameter ‘Transfusion dose density’ allows to incorporate longitudinal 
changes of transfusion intensity in the evaluation of the impact of transfusions on outcome 
• Transfusion dependency may be considered as an indicator of inferior progression-free 
survival, even at relatively low transfusion dose densities 
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Abstract 
 
Progression-free survival of lower-risk myelodysplastic syndromes patients treated with red blood 
cell transfusions is usually reduced, but it is unclear whether transfusion dose density is an 
independent prognostic factor. The European MDS Registry collects prospective data at 6-monthly 
intervals of newly diagnosed lower-risk myelodysplastic syndromes patients from 16 European 
countries and Israel. Data on the transfusion dose density - the cumulative dose received at the end 
of each interval divided by the time since the beginning of the interval in which the first transfusion 
was received - were analyzed using proportional hazards regression with time-varying co-variates, 
with death and progression to higher-risk myelodysplastic syndromes /acute myeloid leukemia as 
events. Of the 1267 patients included in the analyses, 317 patients died without progression, in 162 
patients the disease had progressed. Progression-free survival was significantly associated with age, 
EQ-5D index, baseline WHO classification, bone marrow blast count, cytogenetic risk category, 
number of cytopenias, and country. Transfusion dose density was inversely associated with 
progression-free survival (p<1x10
-4
): dose density had an increasing effect on hazard until a dose 
density of 3 units/16 weeks. The transfusion dose density effect continued to increase beyond 8 
units/16 weeks after correction for the impact of treatment with erythropoietin agents, lenalidomide 
and/or iron chelators. Conclusion: the negative effect of transfusion treatment on progression-free 
survival already occurs at transfusion densities below 3 units/16 weeks. This indicates that 
transfusion dependency, even at relatively low dose densities, may be considered as an indicator of 
inferior progression-free survival.   
This trial was registered at www.clinicaltrials.gov as #NCT00600860. 
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Introduction  
Red blood cell transfusions (RBCT) are the major component of the supportive care of patients with 
myelodysplastic syndromes (MDS). The life expectancy of MDS patients treated with RBCT is usually 
reduced compared with untransfused patients,
1,2
 but whether the impaired outcome is a result of 
intrinsic deterioration of the underlying disease or a result of external factors related to transfusion 
per se (for example the iron toxicity induced by RBCT) remains an open question. The EUMDS registry 
has prospectively collected observational data on patients with low and intermediate-1 risk MDS 
according to IPSS
3
, defined as lower-risk MDS (LR-MDS), since December 2007.
4
 The majority of LR-
MDS patients become transfusion dependent (51% in the EUMDS Registry)
4
, usually within 6 months 
after diagnosis. With an expected median survival of 2.4 to 11.8 years, these patients might be prone 
to long-term accumulation of iron due to RBCT.
3,5-8
 The toxic effects of iron overload in other iron 
loading diseases, such as hereditary hemochromatosis
9
 and the thalassemia syndromes
10
, are well 
known, but the consequences in MDS patients require further clarification. MDS patients are 
generally older than patients with other iron loading disorders
11
. Their exposure to RBCT may not be 
long enough to develop classical tissue damage due to iron overload, but they may suffer from 
oxidative stress caused by toxic iron species, including non-transferrin bound iron (NTBI) and labile 
plasma iron (LPI), which have been suggested to serve as early indicators of iron toxicity in iron 
loading anemias, such as thalassemia syndromes.
8,12
 Biomarkers of oxidative stress have been found 
to be increased in patients with MDS and iron overload.
4,13-16
 Data from a recently completed study 
of the EUMDS Registry
17
 showed that elevated LPI levels - in contrast to elevated NTBI levels and 
TSAT - are associated with decreased survival. The risk of dying prematurely in patients with 
detectable LPI levels occurred too early in this study to explain this risk by classical iron overload due 
to organ toxicity (lungs, liver and heart) after long term transfusions, and this may suggest a direct 
effect associated with elevated LPI levels. 
The aim of this analysis was to assess the effect of RBCT dose density on progression-free survival 
(PFS) of patients with LR-MDS. The hypothesis is that transfusional iron may be toxic and associated 
with oxidative stress, which may lead to BM failure, genetic damage, increased risk for progression or 
premature death. Two countervailing forces may play a role in this analysis: firstly, patients with 
symptomatic anemia are more likely to receive more frequent RBCT. Secondly, higher RBCT doses 
may lead to faster deterioration of LR-MDS or to a higher risk of complications by co-morbidities.
5 
 Methods 
Lower-risk (IPSS risk low or intermediate-1)
3
 patients from 16 European countries and Israel were 
included in the EUMDS registry, after signed informed consent within 100 days of the initial diagnosis 
of a MDS according to WHO 2001 criteria
18
. Patients with an IPSS risk intermediate-2 or high, or with 
therapy-related MDS were excluded, but MDS-specific treatment, started before registration within 
100 days after diagnosis, was not a reason for exclusion. Data were collected at baseline and at each 
6-monthly outpatient routine follow-up visit. Clinical information was collected on: demographics, 
anthropometrics, co-morbidities, performance status, quality of life (EQ-5D), concomitant 
medication, laboratory parameters, diagnostics including information on bone marrow morphology, 
histology, cytogenetics, red blood cell transfusion episodes, total number of transfused units and 
simultaneous therapeutic interventions. All subjects were followed prospectively by full reports 
every 6 months until death, progression to high risk MDS or leukemia, loss to follow-up or 
withdrawal of informed consent. The registry was approved by each institution’s ethics committee 
according to countries legislations. 
 
Transfusion data available in the EUMDS Registry consists of the number of units received between 
each reported visit, usually at 6 months intervals. In order to assess the association between 
transfusions received and progression free survival (PFS), proportional hazards regression with time-
varying covariates was employed, adjusting the effect of transfusions by appropriate baseline and 
time varying variables. For the purposes of the time-to-event analyses, time is measured from date 
of diagnosis with MDS to date of disease progression or date of death. Progression is defined as 
increase to either RAEB-2 or to acute leukemia. Patients without disease progression and still alive at 
time of the analyses were censored at their date of their last visit. 
In order to avoid problems with simultaneity of cause and effect assumed by the proportional 
hazards approach to survival analysis a “dose density” variable was defined for blood transfusions 
received, in the following way. The cumulative total of units of blood received at the end of each 
inter-visit time interval was calculated. This was then divided by the time since the beginning of the 
time interval in which the first post-diagnosis transfusion was received, giving a dose-density 
measurement. This dose-density was then assigned to each time interval. The value of this variable at 
each point in time represents the average rate at which the patient has been receiving units of blood 
since they started transfusions. 
Adjusted baseline variables included: age at diagnosis, number of cytopenias and number of units of 
blood received before diagnosis. Adjusted time-varying variables (with the intention of adjusting for 
6 
the condition of the patient over time) were: bone marrow blast count, EQ5D-index, IPSS-R 
cytogenetic category, platelet and neutrophil counts. Additional analyses were adjusted for the effect 
of ESA treatment, iron chelation therapy and lenalidomide, taking these treatments to be 
confounding factors. Finally, a sensitivity analysis was performed in the survival regressions to take 
into account that the population is not homogeneous but distributed over different centers in several 
countries, using a random effects frailty term. The random effect, called “frailty”, is the term that 
describes the common risk or the individual heterogeneity, acting as a factor on the hazard function. 
Missing values in adjustment variables were imputed with last observation carried forward or next 
observation carried backward. 
 
Results 
Patient characteristics 
The EUMDS Registry contained data from 2,192 patients diagnosed between December 3
rd
, 2007 to 
March 14
th
, 2017 of which 1,504 patients had three or more visits recorded (visit 3 = landmark at 1 
year follow-up). Two patients with RAEB-2 were excluded resulting in the inclusion of 1,502 patients. 
An additional 235 patients were excluded, as one or more of the following variables had never been 
measured or the test failed throughout the study: cytogenetics (n=112), EQ-5D (n=101), blast count 
(n=60), platelets count (n=1) neutrophil count (n=2). The final cohort consisted of 1267 patients, 
unselected for any type of treatment. In 162 patients the disease had progressed to higher-risk MDS 
or acute myeloid leukemia (AML) and 317 patients had died without progression. Median survival 
after disease progression was 5.3 months (95%CI 3.2- 9.8 months). For full details of the exclusions, 
see the supplementary data. Table 1 and supplementary table 1 show the baseline demographics. 
For the landmark analysis patients were defined as untransfused if they had never received a 
transfusion from diagnosis until the end of the study period (death or progression), or if they had 
received transfusion only once (n=751). Patients were defined as transfused if they had received 
multiple transfusions (n=516) within the first year of follow-up (visit 3 = landmark). Regular 
transfusions were initiated usually during the first 6 months. Using visit 3 as the landmark ensured 
that the majority of patients who received more than one transfusion were correctly identified. 
 
Distribution of transfusion dose density 
The distribution of non-zero dose densities at the third visit (the landmark visit) is shown in figure 1. 
Mean dose density amongst those who had received a transfusion at one year of follow-up was 
1.24 units per month, with a median of 0.88 units per month (IQR 0.31 – 1.85). Dose densities of 
7 
the transfused patients declined on approach to the final recorded interval, if patient died or 
progressed to higher-risk MDS during the last interval (supplementary figure 1). This implies that 
patients received fewer transfusions per month in the interval during which death occurred, than in 
the preceding intervals. Presumably, the treatment focus switches to palliative care at home on the 
approach to death. Patients alive at the last recorded visit and no signs of progression did not show 
an increase of the transfusion density over time (supplementary figure 1). 
 
Outcome of patients stratified according to transfusion status at landmark one year after 
registration 
Characteristics at time of landmark visit 3 stratified according the transfusions status are shown in 
supplementary table 2. 145 Subjects untransfused at visit 3, went on to have transfusions after the 
landmark visit. Out of 516 transfused by the time of the landmark 288 subjects were not reported to 
have received any further transfusions, but out of these 288, 125 subjects did not have any further 
visits and a further 91 had only one additional visit. Of the 163 who had an additional visit (91+72), 
73 received treatment with ESA, 19 lenalidomide, 10 hypomethylating agents, 2 hydroxycarbamide, 3 
iron chelators. Unadjusted PFS stratified by transfusion status (transfused n=516, untransfused 
n=751) at the third visit is presented in figure 2A. The overall PFS of the untransfused patients at visit 
3 was significantly better (p <0.0001) compared to the transfused patients.  
Transfused patients were divided into those receiving above (high density) or below (low density) the 
median value (0.87 units per month) of non-zero dose densities. Unadjusted PFS stratified by 
transfusion status and dose density (untransfused n=751, low dose density n=258, high dose 
density=258) at the third visit is presented in figure 2B. The overall PFS of the three groups of 
patients, stratified according to the dose density at visit 3, was significantly different (p <0.0001). We 
evaluated the time to progression in the three groups of patients by censoring those who died before 
progression, see figure 2C . The Hazard ratios of the patients in the low and high density group were 
1.85 (95% CI 1.24, 2.76), and 3.79 (95% CI 2.65, 5.42) relative to the non-transfused group. The 
recently revised IWG hematological response criteria in patients with MDS have refined the RBCT 
burden by dividing patients into 3 categories (non-transfused patients, low transfusion burden (0.75-
2 units per month) and high transfusion burden patients (> 2 units per months)
19
. Therefore, we 
repeated the analysis and subdivided the patients into 4 groups: no transfusions, >0 to <0.75 (low 
transfusion burden), 0.75 to 1.75 (mid transfusion burden) and >1.75 (high transfusion burden). The 
results are shown in figure 2D. The main effect occurred for low dose densities, such that the 
outcome of the mid and high transfusion density group was similar. The low transfusion burden 
8 
group is almost identical to the low burden group (<0.89 units per month) of figure 2B. MDS-related 
causes of death increased from 28% in the non-transfused group to 39% and 48% in the mid and high 
transfusion burden group (data not shown).  
 
Impact of individual prognostic factors 
The univariate effect of various covariates on the outcome was investigated in order to discover the 
appropriate functional form for the covariates (i.e. to discover whether a linear or non-linear form 
was best) and to discover appropriate ways of adjusting for confounding covariates. Increasing RBCT 
dose density was associated with inferior PFS (p<10
-4
). The functional form is shown in figure 3A. The 
effect of the dose density increases until a dose density of about 1 unit per month; thereafter, the 
effect is flat. Baseline age (as continuous variable) was strongly associated with PFS (p<1x10
-4
) in 
univariate regression analyses, as well as baseline MDS diagnosis (p<1x10
-4
), quality of life measured 
by the EQ5D Index (p<1x10
-4
), country (p=0.002), bone marrow blast count (p<1x10
-4
), number of 
cytopenias (p<1x10
-4
), IPSS-R cytogenetic category (p<1x10
-4
), hemoglobin levels (p<1x10
-4
), 
neutrophil levels (p<1x10
-4
) and platelet levels (p<1x10
-4
). No difference in PFS was detected by sex 
(p=0.1), but PFS in females was superior in the multivariate analyses. 
 
Progression-free survival using time-varying covariates proportional hazards regression analysis 
Variables used for adjustment at baseline included age at diagnosis, sex, country of origin, number of 
cytopenias (and their corresponding blood counts), number of units of blood received before 
registration. Time varying variables measured longitudinally included: dose density, EQ5D index, 
components of the IPSS-R, receipt of ESA, iron chelators and lenalidomide. 
In multivariate analysis, not adjusting for the effects of ESA, iron chelation and lenalidomide therapy, 
all variables entered in the regression retained statistical significance. The functional form of the 
dose density effect (p<10
-4
) was as shown in figure 3B. With a frailty term added for the subject 
country, all previously significant variables, including the dose density, retained statistical 
significance, with a dose density p-value of <10
-4
. 
 
Impact of therapeutic interventions on RBCT densities 
Treatment with ESAs, lenalidomide and iron chelators may improve erythropoiesis and reduce the 
need for RBCT. Reduction of the RBCT rate will result in a gradual decrease of the subsequent RBCT 
dose densities in intervals during the response period. Therefore, we investigated how many of the 
9 
transfused patients had been treated with these interventions and calculated the average treatment 
duration and the number of patients with reduced transfusion densities after starting the 
intervention. In our cohort of 1267 patients, 679 of them received treatment with ESA and 151 had 
reduced transfusion densities in the first visit after starting ESA treatment. Supplementary figure 2 
gives the individual dose density over time during ESA treatment of the 151 responding patients. 
Overall, 100 patients received treatment with lenalidomide and of these 53 patients had a reduced 
transfusion density in the first visit after starting lenalidomide treatment; Supplementary figure 3 
shows the individual dose density over time during lenalidomide treatment of the 53 responding 
patients. Within our study group 186 patients received treatment with iron chelators and 75 patients 
had a response leading to reduced transfusion densities in the first interval after start of iron 
chelation treatmen (Supplementary figure 4). In contrast to the dose densities over time during ESA 
and lenalidomide treatment, the pattern of longer term dose densities during iron chelation 
appeared to show a more stable pattern. Subjects receiving a certain level of blood transfusion dose 
when they first receive iron chelation appear to be maintaining that level of dose density. The decline 
of the dose density is less pronounced, but this might be a reflection of the longer transfusion period 
before starting chelation treatment when compared with the other two interventions. 
The observed patterns of dose density trajectories suggest that receiving ESA, lenalidomide and iron 
chelation therapy modulates the dose density and therefore we included these variables in the 
regression model. This analysis resulted in an effect for the dose density similar to the previous 
analyses (figure 3B), with a p-value of <0.0001 indeed all variables entered in the regression retained 
statistical significance, except for platelet count (p=0.47) and neutrophil count (p=0.24). However, 
the dose density effect continues to increase beyond 1 unit per month after correction for the three 
interventions (ESA, iron chelation and lenalidomide) up until a dose of 6 units per month (figure 3C). 
Some patients received more than one intervention simultaneously, including 25 patients who 
received chelation and lenalidomide and 88 patients who received ESA and chelation. However, no 
additional impact could be detected over and above the impact of the two individual interventions. 
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Discussion 
This large prospective, observational study confirmed the reported association of transfusion dose 
density with reduced PFS in patients with LR-MDS.
20
 More surprisingly, we showed in this study that 
this negative association already occurred at a low transfusion rate. In addition, we showed that the 
risk of progression increased both in the low and high transfusion burden group when compared to 
the non-transfused patients. We could even show that the deleterious effect of transfusions 
occurred at a very low transfusion burden (< 0.75 units per month or <3 units per 16 weeks as 
defined in the revised IWG), when the patients were subdivided according to the revised IWG 
hematological response criteria
19
. These patients with a very low transfusion burden are considered 
as untransfused patients using the revised IWG response criteria
19
. 
The main focus of our study was to analyze the association of transfusion rate with outcome, 
assuming that regularly transfused patients may be exposed to the postulated toxicity of RBCT at a 
lower transfusion burden than generally accepted. Several studies have addressed this question 
using various definitions of transfusion rate. The initial publications describing the impact of RBCT on 
outcome in MDS compared RBCT dependent patients with RBCT independent patients, using RBCT 
dependency as a time dependent variable.
1,21
 These studies were based on various definitions of 
RBCT dependency
22,23
, including a study using a rigid criterion, which implied a RBCT rate of at least 1 
unit per month during a period of 2 months.
24
 In this last study, transfusion dependency occurred in 
a minority of the patients (35% to 44%). The use of this definition implies that patients receiving 
regularly less than 3 units per 16 weeks are defined as RBCT independent, but these patients might 
also be subject to the deleterious association with RBCT. In addition, patients may respond to 
therapeutic interventions, such as ESA, lenalidomide or iron chelators and become RBCT 
independent again. The conclusion was that the severity of anemia was the leading cause of impaired 
survival rather than RBCT dependency.
24
 However, the definition of severe anemia (<9 g/dL in males 
and <8 g/dL in females) implies that the majority of these patients were regularly transfused, as 
confirmed in this study.
24
 This study also showed that the transfusion rate was significantly 
associated with an increased risk of cardiac complications. The risk of cardiac complications was 
significantly higher in patients with a RBCT intensity of >3 units per months compared to patients 
transfused with <1 unit per month.
24
 In an open forum discussion RBCT dependency was even 
defined much higher at 2 units per months in a 3-month interval.
25
 A Spanish study in 191 transfused 
patients with MDS used the interval between each transfusion to calculate the transfusion 
intensity.
26
 They concluded that high transfusion intensity was associated with decreased survival 
and increased risk for development of AML in concordance with our study. Interestingly, the 
11 
cumulative transfusion burden was not a prognostic factor when the transfusion intensity was 
included in the model.
26
 
The traditional evaluation of prognostic impact of factors influencing outcome have used standard 
time-to-event methods based on variables at diagnosis, however, many variables in MDS may change 
over time. This aspect can be addressed by using proportional hazards regression with time-varying 
covariates. The EUMDS registry is collecting its observational data at registration of each new patient 
(within 100 days after diagnosis) and follow-up data at six months intervals. This practice leads to 
regular visit intervals of six months. For many patients in this dataset, the value of the recorded 
transfusion rate varies strongly over time, as shown in the supplementary files. Therefore, we 
calculated the RBC rate at each reported visit during all preceding visit intervals between the date of 
the first RBCT and the date of the last visit, leading to a “smoothed” variable, defined as dose 
density. This reflects an average rate of receiving transfusions during the whole observation period 
with transfusions. The relatively low number of RBCT units per months can be explained by the 
remarkable variation of the transfusion rate over time, even when using interval visit reports of 6 
months duration. 
Baseline age, bone marrow percentage category, number of cytopenias, and the EQ5D-index 
retained their significant prognostic impact in the proportional hazards regression with time-varying 
explanatory variables. Also, the non-linear component of the dose density effect was retained (p<10
-
4
). The unfavorable effect of the dose density increased until a dose density of about two units per 
month and leveled off thereafter. A similar form and effect was observed when using the cumulative 
dose of RBCT units over time in an identical multivariate regression model using the same variables 
(data not shown). The negative impact of the cumulative RBCT dose already starts at time of 
administering the first transfusion and does not increase any further beyond 30 units RBCTs received 
(data not shown). 
Many patients showed a (temporary) decrease of the RBCT dose density, reflecting response to 
ESA
27
, lenalidomide
28
, and/or iron chelators
12
 in 22%, 53% and 40% of the treated patients 
respectively. The observed patterns of dose density trajectories suggest that receipt of ESA, 
lenalidomide and iron chelation modulate the dose density and therefore we included these 
variables as confounding variables in the regression model. This analysis showed that the impact of 
the dose density remained similar to the previous analyses, but in contrast to the previous analyses 
there is some evidence that the dose density effect continues to increase beyond 2 units per month 
after correction for the three interventions. 
12 
RBCT are usually administered after a certain storage time, but the survival of stored RBC depends on 
this time.
29
 
30
 Transfusion of stored RBCs leads to pro-inflammatory reactions, associated with a 
higher risk of infection and increased levels of circulating iron and in particular non-transferrin bound 
iron (NTBI) species, which enhance bacterial growth in vitro.
31,32
 Infusion of autologous RBC from 
healthy volunteers after increasing storage up to 6 weeks resulted in increased extravascular 
hemolysis, decreased RBC survival, elevated NTBI and ferritin levels in units transfused after 6 weeks 
compared to units transfused after shorter shortage.
33
 Excess toxic iron species, including NTBI and 
especially its component Labile plasma iron (LPI)
34
 catalyze the cellular generation of reactive oxygen 
species. Oxidative stress may lead to pro-inflammatory responses and to oxidation of lipids, proteins 
and DNA causing cell and tissue damage.
35,36
 Elevated NTBI levels after a single unit of RBC stored for 
6 weeks normalize within 24 hours.
37
 However, in multi-transfused patients (cumulative number of 
units >10) with MDS, NTBI and LPI remained elevated up to the next transfusion.
17
 
Conclusion The negative association of transfusions on PFS already occurs at low RBCT dose densities 
below 3 units per 16 weeks. This indicates that the RBCT dependency in patients transfused at 
relatively low rates, who are usually considered as untransfused patients, may be considered as an 
indicator of poor prognosis for progression-free survival. This poor prognosis in transfusion 
dependent patients might be the result of direct toxicity by the toxic iron radicals resulting from the 
RBCT or the result of concomitant disease progression, including hematopoietic impairment. The 
data in the chelation study from our group in this issue provides support for the direct toxicity of 
RBCT density on outcome, because chelated patients have a better outcome, if treated with 
chelators, which remove toxic iron radicals effectively. Future studies, including interventional 
studies, are needed to confirm our observations, which may lead to adaptations of the current 
recommendations. 
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Tables 
Table 1: Baseline Characteristics from time of diagnosis & PFS, stratified according to transfusion status at landmark (Visit 3)  
 
Total 
 
Hazard Ratio 
(95%CI) 
Adjusted Hazard 
Ratio (95%CI) 
(95%CI) 
 Transfusion Status at landmark 
   
No Yes 
  
        
Total  1267 (100.0)     751 (100.0) 516 (100.0) 
Median age at diagnosis 73.0 (18.0 - 95.0)  1.03 (1.02 - 1.04) 1.03 (1.02 - 1.04)  73.0 (18.0 - 91.0) 73.0 (21.0 - 95.0) 
        
Sex:        
Male 757 (59.7)  1 1  445 (59.3) 312 (60.5) 
Female  510 (40.3)  0.84 (0.70 - 1.01) 0.76 (0.62 - 0.92)  306 (40.7) 204 (39.5) 
        
WHO Diagnosis:        
RA 218 (17.2)  0.84 (0.64 - 1.10) 0.78 (0.59 - 1.03)  139 (18.5) 79 (15.3) 
RARS 214 (16.9)  0.73 (0.56 - 0.96) 0.59 (0.45 - 0.78)  123 (16.4) 91 (17.6) 
RCMD 492 (38.8)  1 1  296 (39.4) 196 (38.0) 
RCMD-RS 86 (6.8)  1.03 (0.72 - 1.46) 0.91 (0.64 - 1.30)  47 (6.3) 39 (7.6) 
RAEB-1 133 (10.5)  1.58 (1.20 - 2.07) 1.86 (1.41 - 2.46)  78 (10.4) 55 (10.7) 
MDS-U 41 (3.2)  0.64 (0.34 - 1.22) 0.68 (0.36 - 1.29)  27 (3.6) 14 (2.7) 
Deletion 5q 83 (6.6)  0.61 (0.40 - 0.92) 0.54 (0.35 - 0.83)  41 (5.5) 42 (8.1) 
        
MDS Comorbidity Index:        
Low 782 (61.7)  1 1  482 (64.2) 300 (58.1) 
Intermediate 411 (32.4)  1.24 (1.02 - 1.50) 1.08 (0.88 - 1.31)  232 (30.9) 179 (34.7) 
High 71 (5.6)  1.55 (1.08 - 2.22) 1.30 (0.90 - 1.89)  35 (4.7) 36 (7.0) 
Not known  3 (0.2)  - -  2 (0.3) 1 (0.2) 
        
Karnofsky Status:        
80-100 881 (69.5)  1 1  543 (72.3) 338 (65.5) 
50-70 210 (16.6)  1.72 (1.38 - 2.15) 1.40 (1.10 - 1.77)  93 (12.4) 117 (22.7) 
10-40 10 (0.8)  2.04 (0.76 - 5.48) 1.89 (0.69 - 5.15)  3 (0.4) 7 (1.4) 
Not known  166 (13.1)  1.08 (0.80 - 1.45) 0.99 (0.73 - 1.34)  112 (14.9) 54 (10.5) 
        
Quality of life        
Visual analogue score, mean (sd) 70.5 (19.7)  0.99 (0.98 - 0.99) 0.99 (0.99 - 1.00)  73.1 (18.9) 66.8 (20.2) 
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Total 
 
Hazard Ratio 
(95%CI) 
Adjusted Hazard 
Ratio (95%CI) 
(95%CI) 
 Transfusion Status at landmark 
   
No Yes 
  
IPSS category        
Low  680 (53.7)  1 1  460 (61.3) 220 (42.6) 
Intermediate  557 (44.0)  1.95 (1.62 - 2.34) 1.71 (1.39 - 2.11)  274 (36.5) 283 (54.8) 
Cytogenetics not done  30 (2.4)  0.83 (0.43 - 1.62) 0.74 (0.38 - 1.45)  17 (2.3) 13 (2.5) 
        
Revised IPSS category         
Very low 386 (30.5)  1 1  310 (41.3) 76 (14.7) 
Low 571 (45.1)  1.80 (1.41 - 2.29) 1.85 (1.45 - 2.37)  309 (41.1) 262 (50.8) 
Intermediate 204 (16.1)  3.19 (2.41 - 4.22) 3.40 (2.55 - 4.52)  89 (11.9) 115 (22.3) 
High 39 (3.1)  4.27 (2.72 - 6.71) 4.59 (2.91 - 7.22)  11 (1.5) 28 (5.4) 
Very high 3 (0.2)  3.15 (0.78 - 12.82) 4.65 (1.13 - 19.15)  1 (0.1) 2 (0.4) 
Not known  64 (5.1)  1.69 (1.07 - 2.68) 1.76 (1.11 - 2.80)  31 (4.1) 33 (6.4) 
        
 
Legend table 1: Baseline characteristics of the included patients from time of diagnosis and progression-free survival, stratified 
according to transfusion status at landmark (Visit 3). 
 
1
Hazard Ratios (HR) & 95% Confidence Intervals (CI) adjusted for all other variables in the table, 
2
Refractory anemia (RA), Refractory anemia with ring sideroblasts (RARS), Refractory cytopenia with multilineage dysplasia 
(RCMD), Refractory cytopenia with multilineage dysplasia & ring sideroblasts (RARS), Myelodysplastic syndrome, unclassifiable 
(MDS-U), 5q-syndrome. 
3
Myelodysplastic syndrome-specific co morbidity index (MDS-CI). 
4
Visual analogue scale (VAS). 
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Figures 
 
Figure 1: Distribution of Dose Densities of all transfused patients in the interval preceding the 
landmark of one year 
 
Legend figure 1:  
Frequency: number of patients in each dose dose density ranging from >0 to 0.2 units per month to 
>6 units per month 
 
 
Figure 2: Progression-free survival and risk of progression according to transfusion status at 
landmark of visit 3 (1 year after registration) 
 
Legend figure 2:  
A; Kaplan-Meijer plot of progression-free survival of patients receiving transfusions by landmark (visit 
3) versus not receiving transfusions. B; Kaplan-Meijer plot of progression-free survival of patients 
receiving transfusions at a low density (<0.87 units/month) by landmark or at a high density (>0.87 
units/month) versus not receiving transfusions; C; Kaplan-Meijer plot of time to progression of 
patients surviving till progression subdivided according to transfusion burden or not as in figure B; D; 
Kaplan-Meijer plot of progression-free survival of patients receiving transfusions at densities 
according to the revised IWG criteria: low dose density: >0- <0.75 units/month; mid dose density: 
0.75 to 1.75 units per months; high dose density >1.75 units per month. 
 
Figure 3: Influence of dose density on progression-free survival 
Legend figure 3: 
A; Dose density effect on progression-free survival (PFS) in an univariate analysis. B; Dose density 
effect on PFS in a multivariate regression model unadjusted for the three treatment variables. C; 
Dose density effect on PFS in a multivariate regression model adjusted for treatment with either ESA, 
Iron Chelation or Lenalidomide. 
 
 



Supplementary Material 
 
 
Supplementary Method Section 
Data Handling and Exclusions 
The dataset contained data from 1504 patients having three or more visits recorded. Within this 
dataset, there were 368 deaths and 181 progressions to high-risk MDS or AML, which were 
considered as events for this analysis. The following exclusions were made: 
x 2 patients with RAEB-2 were removed leaving 1502 patients. 
x 1 patient was deleted as the subject had a very long pre-diagnosis transfusion history. 
 
These exclusions leave 1501 patients in the cohort. 
We also removed all patients that had completely missing values for any of the following variables: 
Haemoglobin (0 patients have all observations missing), neutrophils (2 patients), platelets (1 
patient), bone marrow blast count (60 patients), cytogenetic risk category (112 patients), EQ5D-
index (101 patients). 
This left a total of 1267 patients in the analysis dataset, with 407 deaths of which 90 had 
progression. 72 Patients survived until the end of the study period but progressed to high-risk MDS 
or AML.   
For the analysis dataset, missing values in these variables were imputed with last observation carried 
forward or next observation carried back. 
 
Handling of missing transfusion data 
10 remaining subjects were flagged as having received transfusions before diagnosis, but were 
missing the number of units received. Those 4 transfused more than a year before diagnosis were 
set to no transfusions received. Those 6 transfused less than a year before diagnosis were assigned 
either an imputed 2 units (a plausible figure) or 4 units (the mean number received among those 
receiving pre-diagnosis transfusion) according to the actual length of time before diagnosis. 
Six additional subjects were identified as having received transfusions a very long time before 
diagnosis (more than 600 days). These patients were set to not having received pre-diagnosis 
transfusions unless they had received more than 7 units (3 patients).  
 The Definition of Dose Density 
For each patient, the transfusion data available consisted of the number of units received between 
ĞĂĐŚǀŝƐŝƚ ?dŚŝƐǀĂƌŝĂďůĞ ?ǁŚŝĐŚǁĞĐĂůůĚŽƐĞ ?ŝƐĞǆƉƌĞƐƐĞĚĂƐĂŶĂǀĞƌĂŐĞŽĨ “ƵŶŝƚƐƌĞĐĞŝǀĞĚƉĞƌŵŽŶƚŚ ? 
in each inter-visit interval. 
The analysis used is proportional hazards regression with time-varying covariates. The basic interval 
on which all variables are defined is the interval between visits. Therefore, covariates are assigned to 
be piecewise constant on these time intervals. 
In standard survival analysis, the hazard at any instant is assumed to be modified by the value of the 
explanatory variables at that instant.  This presented three problems for the analysis with the dose 
transfusion variable: 
x For many patients in this dataset, the value of the recorded transfusion dose variable is very 
 “ƐƉŝŬǇ ? ? ǀĂƌǇŝŶŐ ƐƚƌŽŶŐůǇ ŽǀĞƌ ƚŝŵĞ ? /ƚ ƐĞĞŵƐ ƵŶůŝŬĞůǇƚŚĂƚ ƚŚĞ ĂĐƚƵĂů ǀĂůƵĞ ŽĨ ƚŚĞ ŚĂǌĂƌĚ
would follow such a form.  
x It is unlikely that the hazard will respond instantaneously to the transfusion dose received. 
x It is observed that, in this dataset, patients receive fewer transfusions in the interval in 
which death occurs, than in the intervals before the interval in which death occurs 
(Supplement figure 1). Presumably, the treatment focus switches to palliative care on the 
approach to death. This would mean that the event of death is correlated with zero or low 
values of transfusion dose, leading to a hazard estimate that is high for low values of dose 
and which reduces as dose increases. 
 
Rather, it seems more likely that the association between transfusions and hazard would be better 
expressed as an association with some sort of cumulative dose value (reflecting the idea that the 
ŚĂǌĂƌĚ Ăƚ ĂŶǇ ƚŝŵĞ ŝƐ ƉƌŽƉŽƌƚŝŽŶĂů ƚŽ ƚŚĞ ƚŽƚĂů ĚŽƐĞ ƌĞĐĞŝǀĞĚ ?Žƌ ǁŝƚŚ ƐŽŵĞ ŽƚŚĞƌ  “ƐŵŽŽƚŚĞĚ ?
variable that reflects an average rate of receiving transfusions.  
In order to perform this smoothing, the cumulative total dose at the end of each inter-visit time 
interval was calculated. This was then divided by the time (in months) since the beginning of the 
time interval in which the first post-diagnosis transfusion was received, giving a dose-density 
measurement. This dose-density is then assigned to each time interval. The value of this variable at 
each point in time represents the average rate at which the patient has been receiving units of blood 
since they started transfusions. This main variable of interest, the dose density, was modelled in 
regression analysis using restricted cubic splines with four knots. 
With the dose density defined as such, the hazard is taken as proportional to the number of units 
received since transfusions started divided by the time since transfusions started. The effect of this is 
to allow the hazard to depend upon something that has happened in the past; but the strength of 
the effect will decay as time passes and no further transfusions are received. Contrast this with 
simply using the cumulative number of units received at any point in time. Here, again, the effect on 
the hazard is proportional to the dose received in the past, but there is now no decay in the size of 
the effect. 
Results 
Supplementary Table 1: Baseline Characteristics from time of diagnosis & PFS, stratified according to transfusion status at 
landmark (Visit 3) 
 
Total 
 
Hazard Ratio 
(95%CI) 
Adjusted Hazard 
Ratio
1
 (95%CI) 
(95%CI) 
 Transfusion Status at landmark 
 
  
No yes 
  
        
 Total  1267 (100.0)     751 (100.0) 516 (100.0) 
Country:         
Austria 86 (6.8)  0.84 (0.56 - 1.27) 0.76 (0.49 - 1.18)  61 (8.1) 25 (4.8) 
Czech Republic 94 (7.4)  0.82 (0.57 - 1.19) 0.89 (0.61 - 1.31)  43 (5.7) 51 (9.9) 
Denmark 47 (3.7)  1.94 (1.25 - 3.02) 1.97 (1.26 - 3.07)  17 (2.3) 30 (5.8) 
France 313 (24.7)  1 1  200 (26.6) 113 (21.9) 
Germany 25 (2.0)  1.09 (0.62 - 1.94) 1.34 (0.75 - 2.40)  17 (2.3) 8 (1.6) 
Greece 128 (10.1)  0.85 (0.60 - 1.20) 0.90 (0.63 - 1.30)  81 (10.8) 47 (9.1) 
Israel 67 (5.3)  0.83 (0.46 - 1.47) 0.92 (0.51 - 1.64)  47 (6.3) 20 (3.9) 
Italy 46 (3.6)  0.47 (0.23 - 0.96) 0.62 (0.30 - 1.27)  33 (4.4) 13 (2.5) 
Netherlands 44 (3.5)  0.75 (0.44 - 1.29) 0.96 (0.56 - 1.65)  28 (3.7) 16 (3.1) 
Poland 31 (2.4)  1.96 (1.19 - 3.22) 1.45 (0.85 - 2.47)  13 (1.7) 18 (3.5) 
Portugal 2 (0.2)  - -  0 (0.0) 2 (0.4) 
Romania 17 (1.3)  0.28 (0.09 - 0.87) 0.15 (0.05 - 0.50)  7 (0.9) 10 (1.9) 
Serbia 14 (1.1)  2.02 (0.94 - 4.33) 1.32 (0.61 - 2.87)  5 (0.7) 9 (1.7) 
Spain 85 (6.7)  1.01 (0.67 - 1.53) 1.18 (0.77 - 1.79)  54 (7.2) 31 (6.0) 
Sweden 88 (6.9)  0.87 (0.61 - 1.24) 0.99 (0.68 - 1.43)  45 (6.0) 43 (8.3) 
United Kingdom 180 (14.2)  0.99 (0.75 - 1.32) 1.07 (0.80 - 1.44)  100 (13.3) 80 (15.5) 
        
Ring  Sideroblasts:        
No 967 (76.3)  1 1  581 (77.4) 386 (74.8) 
Yes 300 (23.7)  0.83 (0.68 - 1.03) 0.78 (0.63 - 0.98)  170 (22.6) 130 (25.2) 
        
IPSS cytogenetic score         
Good 1052 (83.0)  1 1  655 (87.2) 397 (76.9) 
Intermediate 170 (13.4)  1.87 (1.49 - 2.35) 1.92 (1.52 - 2.43)  73 (9.7) 97 (18.8) 
Poor 15 (1.2)  2.30 (1.18 - 4.46) 2.36 (1.21 - 4.60)  6 (0.8) 9 (1.7) 
Cytogenetics not done 30 (2.4)  0.68 (0.35 - 1.32) 0.68 (0.35 - 1.32)  17 (2.3) 13 (2.5) 
        
        
 
Total 
 
Hazard Ratio 
(95%CI) 
Adjusted Hazard 
Ratio
1
 (95%CI) 
(95%CI) 
 Transfusion Status at landmark 
 
  
No yes 
  
Revised IPSS cytogenetic score        
Very good 121 (9.6)  0.94 (0.66 - 1.33) 0.86 (0.60 - 1.23)  87 (11.6) 34 (6.6) 
Good 963 (76.0)  1 1  594 (79.1) 369 (71.5) 
Intermediate 141 (11.1)  2.56 (2.02 - 3.25) 2.47 (1.93 - 3.15)  55 (7.3) 86 (16.7) 
Poor/ Very Poor 23 (1.8)  1.41 (0.75 - 2.65) 1.26 (0.67 - 2.38)  9 (1.2) 14 (2.7) 
Not known 19 (1.5)  1.81 (0.99 - 3.29) 1.63 (0.89 - 3.00)  6 (0.8) 13 (2.5) 
        
Legend: Baseline characteristics of the included patients from time of diagnosis and progression-free survival, stratified according 
to transfusion status at landmark (Visit 3).  
1
Hazard Ratios (HR) & 95% Confidence Intervals (CI) adjusted for all other variables, as described in Table 1 in the manuscript, 
 
Supplementary Table 2 Characteristics at time of landmark Visit 3 stratified according to transfusion 
status at landmark (Visit 3) 
 
Total 
 Transfusion Status at landmark 
  
No Yes 
 
     
 Total  1267 (100.0)  751 (100.0) 516 (100.0) 
Median age at visit 3  74.5 (20.1 - 96.3)  74.2 (20.1 - 92.9) 74.8 (22.2 - 96.3) 
     
WHO Diagnosis
2
:     
RA 130 (10.3)  82 (10.9) 48 (9.3) 
RARS 166 (13.1)  91 (12.1) 75 (14.5) 
RCMD 328 (25.9)  190 (25.3) 138 (26.7) 
RCMD-RS 46 (3.6)  23 (3.1) 23 (4.5) 
RAEB-1 103 (8.1)  57 (7.6) 46 (8.9) 
RAEB-2 30 (2.4)  5 (0.7) 25 (4.8) 
MDS-U 27 (2.1)  21 (2.8) 6 (1.2) 
Deletion 5q 70 (5.5)  31 (4.1) 39 (7.6) 
Bone Marrow not done 367 (29.0)  251 (33.4) 116 (22.5) 
     
MDS-CI
3
:      
Low 928 (73.2)  583 (77.6) 345 (66.9) 
Intermediate 293 (23.1)  154 (20.5) 139 (26.9) 
High 35 (2.8)  10 (1.3) 25 (4.8) 
Not known  11 (0.9)  4 (0.5) 7 (1.4) 
     
Karnofsky Status:     
80-100 738 (58.2)  496 (66.0) 242 (46.9) 
50-70 205 (16.2)  74 (9.9) 131 (25.4) 
10-40 25 (2.0)  11 (1.5) 14 (2.7) 
Not known  299 (23.6)  170 (22.6) 129 (25.0) 
     
Quality of life      
Visual analogue score, mean  (sd) 69.7 (19.0)  73.6 (18.5) 64.1 (18.2) 
     
Revised IPSS category       
Very low 384 (30.3)  305 (40.6) 79 (15.3) 
Low 576 (45.5)  314 (41.8) 262 (50.8) 
Intermediate 203 (16.0)  88 (11.7) 115 (22.3) 
High 45 (3.6)  16 (2.1) 29 (5.6) 
Very high 4 (0.3)  1 (0.1) 3 (0.6) 
Not known  55 (4.3)  27 (3.6) 28 (5.4) 
     
2
Refractory anemia (RA), Refractory anemia with ring  sideroblasts (RARS), Refractory cytopenia with 
multilineage dysplasia (RCMD), Refractory cytopenia with multilineage dysplasia & ring  sideroblasts 
(RARS), Refractory anemia ǁŝƚŚĞǆĐĞƐƐďůĂƐƚƐ ? ? ?Z ?/ ? ? Refractory anĞŵŝĂǁŝƚŚĞǆĐĞƐƐďůĂƐƚƐ ? ?
 ?Z ?II), Refractory anĞŵŝĂǁŝƚŚĞǆĐĞƐƐďůĂƐƚƐ ? ? ?Z ?// ? ?DǇĞůŽĚǇƐƉůĂƐƚŝĐƐǇŶĚƌŽŵĞ ?ƵŶĐůĂƐƐŝĨŝĂďůĞ
 ?D^ ?h ? ? 
3DǇĞůŽĚǇƐƉůĂƐƚŝĐƐǇŶĚƌŽŵĞ ?ƐƉĞĐŝĨŝĐĐŽŵŽƌďŝĚŝƚǇŝŶĚĞǆ ?D^ ?/ ? ?  
  
Supplementary figure 1: Mean number of transfused units per month, counting back from the final 
interval before death, transformation (solid line)  or censoring for last interval report, alive and well 
(broken line). 
 
 
 
 
Supplementary figure 2 Dose Density Trajectories for all Subjects with Initial Response to ESA. 
 
 
  
Supplementary figure 3 Dose Density Trajectories for all Subjects with Initial Response to 
Lenalidomide. 
 
 
 
Supplementary figure 4 Dose Density Trajectories for all Subjects with Initial Response to Iron 
Chelation. 
 
